Audio

Community Oncology Podcast - Axitinib and sorafenib in advanced renal cell carcinoma.


 

Editor-in-Chief Dr. David H. Henry takes you on an audio tour of the July issue including discussions of an original research report on the impact of depression on cancer comorbidity and this month's Community Translation: Axitinib and sorafenib in second-line treatment of advanced renal cell carcinoma.

Recommended Reading

FDA Warns of QT Prolongation with Ondansetron Dose
MDedge Hematology and Oncology
FDA Approves REMS for Long-Acting Opioids
MDedge Hematology and Oncology
Studies Clash on Cardiac Effects of TKIs in Kidney Cancer
MDedge Hematology and Oncology
Platinum Levels Linked to Toxicity in Testicular Cancer Survivors
MDedge Hematology and Oncology
QoL Steadies 15 Years After Prostate Cancer Treatments
MDedge Hematology and Oncology
ASCO Weighs in on PSA Screening Controversy
MDedge Hematology and Oncology
Surgery Didn't Cut Mortality from PSA-Detected Prostate Cancer
MDedge Hematology and Oncology
Washington Post Blasts Proliferation of ESAs for Anemia
MDedge Hematology and Oncology
Traffic-Related Toxins Linked to Childhood Kidney Cancer
MDedge Hematology and Oncology
Would Advanced Prostate Cancer Triple Without PSA Screening?
MDedge Hematology and Oncology